Antibody-mediated immune suppression is improved when blends of anti-RBC monoclonal antibodies are used in mice

Blood

Volumn 128, Issue 8, 2016, Pages 1076-1080

  Bernardo, Lidice ^a   Amash, Alaa ^a   Marjoram, Danielle ^a   Lazarus, Alan H ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F4; MONOCLONAL ANTIBODY 4B7; MONOCLONAL ANTIBODY 5B9; MONOCLONAL ANTIBODY 8E12; UNCLASSIFIED DRUG; LYSOZYME;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY MEDIATED IMMUNE SUPPRESSION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NEWBORN HEMOLYTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; STEREOSPECIFICITY; ANIMAL; C57BL MOUSE; CHICKEN; ERYTHROCYTE; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CHICKENS; ERYTHROCYTES; HUMANS; IMMUNOSUPPRESSION; MICE, INBRED C57BL; MURAMIDASE;

EID: 85017256826     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-692178     Document Type: Article

References (15)

1. Kumpel BM. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. Clin Exp Immunol. 2008; 154(1):1-5.
2. Olovnikova NI, Belkina EV, Drize NI, et al. [Fast clearance of the rhesus-positive erythrocytes by monoclonal anti-rhesus antibodies-an insufficient condition for effective prophylaxis of rhesussensitization]. Biull Eksp Biol Med. 2000;129(1): 77-81.
3. Easdale S, Stasi R. Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia. Expert Opin Biol Ther. 2013;13(7):1085-1092.
4. Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood. 2012;120(18):3670-3676.
5. Desmarets M, Cadwell CM, Peterson KR, Neades R, Zimring JC. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood. 2009;114(11):2315-2322.
6. Yu H, Stowell SR, Bernardo L, et al. Antibodymediated immune suppression of erythrocyte alloimmunization can occur independently from red cell clearance or epitope masking in a murine model. J Immunol. 2014;193(6):2902-2910.
7. Zimring JC, Cadwell CM, Chadwick TE, et al. Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes. Blood. 2007; 110(6):2201-2208.
8. Zimring JC, Hair GA, Chadwick TE, et al. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood. 2005;106(3): 1105-1112.
9. Freedman J, Lazarus AH. Applications of flow cytometry in transfusion medicine. Transfus Med Rev. 1995;9(2):87-109.
10. Bernardo L, Yu H, Amash A, Zimring JC, Lazarus AH. IgG-Mediated Immune Suppression to Erythrocytes by Polyclonal Antibodies Can Occur in the Absence of Activating or Inhibitory Fcγ Receptors in a Full Mouse Model. J Immunol. 2015;195(5):2224-2230.
11. Getahun A, Heyman B. Studies on the mechanism by which antigen-specific IgG suppresses primary antibody responses: evidence for epitope masking and decreased localization of antigen in the spleen. Scand J Immunol. 2009;70(3):277-287.
12. Na D, Kim D, Lee D. Mathematical modeling of humoral immune response suppression by passively administered antibodies in mice. J Theor Biol. 2006;241(4):830-851.
13. Karlsson MC, Wernersson S, Diaz de Ståhl T, Gustavsson S, Heyman B. Efficient IgGmediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. Proc Natl Acad Sci USA. 1999;96(5): 2244-2249.
14. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
15. Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 2007;93(2): 99-111.